|
|
Article: Shares In Myogen Skyrocket On Phase II Hypertension Data.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Myogen Inc. saw its stock surge by more than 60 percent Thursday on positive Phase IIb data generated by its investigational hypertension drug, darusentan, which works by way of a different mechanism than the range of hypertension products already on the market.
"This is an indication which, by definition, there are no other alternatives," Myogen President and CEO Bill Freytag told BioWorld Today, noting that eligible patients already were taking three other hypertension drugs without relief. "And in spite of that, you still have hypertension that is above targets that have been identified as significantly lowering your risk for ...